Alzheimer’s and Neurodegenerative Disease Treatment (20110150, Dr. Robert Vince)

Technology No. 20110150
IP Status: Issued US Patent; Application #: 14/131,655

GSH Analogs

A pharmaceutical compound consisting of stable glutathione (GSH) analogs has been developed to treat Alzheimer's disease (AD) and other neurodegenerative disorders. The GSH analogs fulfill key roles of endogenous GSH and resist enzyme breakdown while acting as a substrate for the detoxifying enzyme glyoxalase-I.

Decreases Glycation and Amyloid-beta Plaques

The GSH analogs treat AD through two mechanisms. Amyloid-beta (Aβ) plaques, a hallmark of AD and other neurodegenerative diseases, are caused by Aβ protein aggregation. Aβ aggregation is induced through glycation. Glyoxalase-I curbs glycation; but this process is dependent on GSH, which is severely depleted in an AD-affected brain. The new GSH analogs treat AD progression by restoring glyoxalase-I activity in the brain, which decreases glycation, and hampers glycation-induced Aβ aggregation, and in turn, plaque formation.

Neutralizes Oxidative Stress

The GSH analogs are able to pass through the blood-brain barrier to neutralize oxidative stress in the brain. Oxidative stress is a root cause of neurodegenerative disorders, as well as other diseases.

Replicates Endogenous GSH Activity

The new GSH analogs are the first compounds to replicate endogenous GSH activity while resisting breakdown. Other compounds which have tried to mimic the role of GSH failed because they were not resistant to breakdown. This treatment could be used in conjunction with other AD treatments, or used independently. This AD treatment can be used earlier than any other existing treatments.

Hepatoprotective Qualities

Separately, the GSH analogs were found to have hepatoprotective qualities. The analogs react directly with N-acetyl-p-benzoquinoneimine (NAPQI), a toxic by-product produced during acetaminophen metabolism. Using the GSH analogs in combination with acetaminophen could improve overall safety. The analogs could also act as a rescue treatment for acute acetaminophen overdose.


  • Helps prevent harmful glycation and Aβ plaque formation
  • Treats AD earlier than other treatments
  • Can be used in combination with other treatments or independently
  • Antioxidant properties treats root cause of neurodegenerative disease
  • Has hepatoprotective qualities and could be used with acetaminophen

Phase of Development In vitro and in vivo data available

Robert Vince, PhD
Director, Center for Drug Design
External Link (
Swati More, PhD
Assistant Professor, Center for Drug Design
External Link (

  • swap_vertical_circlelibrary_booksReferences (0)
  • swap_vertical_circlecloud_downloadDownloads (0)
    Files marked with an asterix (*) can only be downloaded by users that have the appropriate product licence. The licence must be active and you must be logged into your account.
Questions about this technology?